background
sinc
decemb
wuhan
china
experienc
outbreak
coronaviru
diseas
caus
sever
acut
respiratori
syndrom
coronaviru
epidemiolog
clinic
characterist
patient
report
risk
factor
mortal
detail
clinic
cours
ill
includ
viral
shed
well
describ
retrospect
multicentr
cohort
studi
includ
adult
inpati
year
old
laboratoryconfirm
jinyintan
hospit
wuhan
pulmonari
hospit
wuhan
china
discharg
die
jan
demograph
clinic
treatment
laboratori
data
includ
serial
sampl
viral
rna
detect
extract
electron
medic
record
compar
survivor
nonsurvivor
use
univari
multivari
logist
regress
method
explor
risk
factor
associ
inhospit
death
multivari
regress
show
increas
odd
inhospit
death
associ
older
age
odd
ratio
ci
per
year
increas
higher
sequenti
organ
failur
assess
sofa
score
p
ddimer
greater
admiss
median
durat
viral
shed
day
iqr
survivor
detect
death
nonsurvivor
longest
observ
durat
viral
shed
survivor
day
interpret
potenti
risk
factor
older
age
high
sofa
score
ddimer
greater
could
help
clinician
identifi
patient
poor
prognosi
earli
stage
prolong
viral
shed
provid
rational
strategi
isol
infect
patient
optim
antivir
intervent
futur
decemb
wuhan
citi
capit
hubei
provinc
china
becam
centr
outbreak
pneumonia
unknown
caus
jan
chines
scientist
isol
novel
coronaviru
sever
acut
respiratori
syndrom
coronaviru
previous
known
patient
virusinfect
pneumonia
later
design
coronaviru
diseas
februari
although
outbreak
like
start
zoonot
transmiss
event
associ
larg
seafood
market
also
trade
live
wild
anim
soon
becam
clear
effici
persontoperson
transmiss
also
occur
clinic
spectrum
infect
appear
wide
encompass
asymptomat
infect
mild
upper
respiratori
tract
ill
sever
viral
pneumonia
respiratori
failur
even
death
mani
patient
hospitalis
pneumonia
wuhan
although
case
seri
publish
mani
patient
seri
remain
hospitalis
time
public
knowledg
previou
studi
done
among
patient
definit
outcom
estim
risk
factor
sever
diseas
death
earlier
case
seri
therefor
robust
addit
detail
clinic
virolog
cours
ill
yet
well
describ
present
detail
patient
admit
two
design
hospit
wuhanjinyintan
hospit
wuhan
pulmonari
hospitalwith
laboratoryconfirm
definit
clinic
prof
hua
chen
depart
tuberculosi
respiratori
diseas
jinyintan
hospit
dongxihu
district
wuhan
china
qqcom
outcom
death
discharg
jan
aim
explor
risk
factor
inhospit
death
patient
describ
clinic
cours
symptom
viral
shed
tem
poral
chang
laboratori
find
hospitalis
retrospect
cohort
studi
includ
two
cohort
adult
inpati
year
old
jinyintan
hospit
wuhan
pulmonari
hospit
wuhan
china
adult
patient
diagnos
accord
interim
guidanc
screen
die
discharg
dec
ie
first
patient
admit
jan
includ
studi
sinc
two
hospit
design
hospit
transfer
patient
hospit
wuhan
feb
studi
enrol
adult
inpati
hospitalis
definit
outcom
dead
discharg
earli
stage
outbreak
jan
rna
detect
result
avail
electron
medic
record
data
studi
obtain
retrospect
therefor
studi
includ
patient
origin
report
studi
approv
research
ethic
commiss
jinyintan
hospit
requir
inform
consent
waiv
ethic
commiss
describ
previous
epidemiolog
demograph
clinic
laboratori
treatment
outcom
data
extract
electron
medic
record
use
standardis
data
collect
form
modifi
version
intern
sever
acut
respiratori
emerg
infect
consortium
case
record
form
sever
acut
respiratori
infect
data
check
two
physician
fz
zl
third
research
gf
adjud
differ
interpret
two
primari
review
method
laboratori
confirm
infect
describ
elsewher
briefli
four
institutionsth
chines
center
diseas
control
prevent
chines
academi
medic
scienc
academi
militari
medic
scienc
wuhan
institut
virolog
chines
academi
scienceswer
respons
detect
respiratori
specimen
nextgener
sequenc
realtim
rtpcr
method
jan
rna
detect
local
center
diseas
control
prevent
local
health
institut
jingyintan
hospit
wuhan
pulmonari
hospit
throatswab
specimen
obtain
pcr
reexamin
everi
day
clinic
remiss
symptom
includ
fever
cough
dyspnoea
qualit
data
avail
criteria
discharg
absenc
fever
least
day
substanti
improv
lung
chest
ct
clinic
remiss
respiratori
symptom
two
throatswab
sampl
neg
rna
obtain
least
h
apart
routin
blood
examin
complet
blood
count
coagul
profil
serum
biochem
test
includ
renal
liver
function
creatin
kinas
lactat
dehydrogenas
electrolyt
myocardi
enzym
serum
ferritin
evid
studi
search
pubm
feb
articl
document
risk
factor
mortal
viral
shed
patient
coronaviru
diseas
covid
result
infect
sever
acut
respiratori
syndrom
coronaviru
use
search
term
novel
coronaviru
death
mortal
viral
shed
languag
time
restrict
age
comorbid
lymphocytopenia
elev
alanin
aminotransferas
ddimer
creatin
kinas
highsensit
cardiac
troponin
prothrombin
time
diseas
sever
report
associ
intens
care
unit
admiss
howev
publish
work
found
risk
factor
mortal
adult
patient
one
studi
compar
sensit
rna
detect
throat
nasopharyng
swab
patient
retrospect
cohort
studi
adult
inpati
two
hospit
wuhan
china
found
increas
odd
inhospit
death
associ
older
age
odd
ratio
ci
higher
sequenti
organ
failur
assess
sofa
score
p
ddimer
level
greater
admiss
durat
viral
shed
rang
day
median
durat
viral
shed
day
iqr
survivor
continu
death
fatal
case
older
age
elev
ddimer
level
high
sofa
score
could
help
clinician
identifi
earli
stage
patient
poor
prognosi
prolong
viral
shed
provid
rational
strategi
isol
infect
patient
optim
antivir
intervent
futur
procalcitonin
chest
radiograph
ct
scan
also
done
inpati
frequenc
examin
determin
treat
physician
fever
defin
axillari
temperatur
least
sepsi
septic
shock
defin
accord
third
intern
consensu
definit
sepsi
septic
shock
secondari
infect
diagnos
patient
show
clinic
symptom
sign
pneumonia
bacteraemia
posit
cultur
new
pathogen
obtain
lower
respiratori
tract
specimen
qualifi
sputum
endotrach
aspir
bronchoalveolar
lavag
fluid
blood
sampl
admiss
ventilatorassoci
pneumonia
diagnos
accord
guidelin
treatment
hospitalacquir
ventilatorassoci
pneumonia
acut
kidney
injuri
diagnos
accord
kdigo
clinic
practic
guidelin
acut
respiratori
distress
syndrom
ard
diagnos
accord
berlin
definit
acut
cardiac
injuri
diagnos
serum
level
cardiac
biomark
eg
highsensit
cardiac
troponin
percentil
upper
refer
limit
new
abnorm
shown
electrocardiographi
echocardiographi
ill
sever
defin
accord
chines
manag
guidelin
version
coagulopathi
defin
extens
pro
thrombin
time
extens
activ
partial
thromboplastin
time
hypoproteinaemia
defin
blood
albumin
less
gl
exposur
histori
defin
exposur
peopl
confirm
infect
wuhan
seafood
market
continu
categor
variabl
present
median
iqr
n
respect
use
mannwhitney
u
test
test
fisher
exact
test
compar
differ
survivor
nonsurvivor
appropri
explor
risk
factor
associ
inhospit
death
univari
multivari
logist
regress
model
use
consid
total
number
death
studi
avoid
overfit
model
five
variabl
chosen
multivari
analysi
basi
previou
find
clinic
constraint
previou
studi
shown
blood
level
ddimer
sequenti
organ
failur
assess
sofa
score
higher
critic
ill
fatal
case
wherea
lymphopenia
cardiovascular
diseas
less
commonli
observ
noncrit
surviv
patient
infect
troponin
creatin
kinas
ddimer
serum
ferritin
might
unavail
emerg
circumst
therefor
chose
lymphocyt
count
ddimer
sofa
score
coronari
heart
diseas
age
five
variabl
multivari
logist
regress
model
exclud
variabl
univari
analysi
betweengroup
differ
signific
accuraci
unconfirm
eg
exposur
selfreport
number
event
small
calcul
odd
ratio
colinear
sofa
score
compar
patient
characterist
two
hospit
use
generalis
linear
model
adjust
possibl
differ
patient
characterist
treatment
two
studi
centr
twosid
less
consid
statist
signific
statist
analys
done
use
sa
softwar
version
unless
otherwis
indic
funder
studi
role
studi
design
data
collect
data
analysi
data
interpret
write
report
correspond
author
bc
hc
full
access
data
studi
final
respons
decis
submit
public
adult
patient
hospitalis
jinyintan
hospit
wuhan
pulmonari
hospit
jan
exclud
patient
still
hospitalis
confirm
rna
detect
jan
nine
inpati
without
avail
key
inform
medic
record
includ
inpati
jinyintan
hospit
wuhan
pulmonari
hospit
final
analysi
patient
die
hospitalis
discharg
median
age
patient
year
iqr
rang
year
year
patient
male
tabl
co
morbid
present
nearli
half
patient
hypertens
common
comorbid
follow
diabet
coronari
heart
diseas
tabl
common
symptom
admiss
fever
cough
follow
sputum
product
fatigu
tabl
lymphocytopenia
occur
patient
patient
receiv
antibiot
receiv
antivir
lopinavirritonavir
tabl
systemat
corticosteroid
intraven
immunoglobulin
use
differ
significantli
nonsurvivor
survivor
tabl
comparison
characterist
treatment
outcom
patient
two
hospit
shown
appendix
pp
median
time
ill
onset
ie
admiss
discharg
day
iqr
wherea
median
time
death
day
tabl
patient
requir
invas
mechan
ventil
die
median
time
ill
onset
invas
mechan
ventil
day
extracorpor
membran
oxygen
use
three
patient
none
surviv
sepsi
frequent
observ
complic
follow
respiratori
failur
ard
heart
failur
septic
shock
tabl
half
nonsurvivor
experienc
secondari
infect
ventilatorassoci
pneumonia
occur
ten
patient
requir
invas
mechan
ventil
frequenc
complic
higher
nonsurvivor
survivor
tabl
univari
analysi
odd
inhospit
death
higher
patient
diabet
coronari
heart
diseas
tabl
age
lymphopenia
leucocytosi
elev
alt
lactat
dehydrogenas
highsensit
cardiac
troponin
creatin
kinas
ddimer
serum
ferritin
prothrombin
time
creatinin
procalcitonin
also
associ
death
tabl
includ
patient
complet
data
variabl
nonsurvivor
survivor
multivari
logist
regress
model
found
older
age
higher
sofa
score
ddimer
greater
admiss
associ
increas
odd
death
tabl
adjust
studi
centr
generalis
linear
model
show
similar
result
appendix
p
survivor
median
durat
viral
shed
day
iqr
ill
onset
viru
continu
detect
death
nonsurvivor
tabl
figur
shortest
observ
durat
viral
shed
among
survivor
day
wherea
longest
day
among
patient
receiv
lopinavirritonavir
discharg
median
time
ill
onset
initi
antivir
treatment
day
iqr
median
durat
viral
shed
day
median
durat
viral
shed
day
patient
sever
diseas
statu
day
patient
critic
diseas
statu
major
laboratori
marker
track
ill
onset
figur
baselin
lymphocyt
count
significantli
higher
survivor
nonsurvivor
survivor
lymphocyt
count
lowest
day
ill
onset
improv
hospitalis
wherea
sever
lymphopenia
observ
death
nonsurvivor
level
ddimer
highsensit
cardiac
troponin
serum
ferritin
lactat
dehydrogenas
clearli
elev
nonsurvivor
compar
survivor
throughout
clinic
cours
increas
ill
deterior
figur
nonsurvivor
highsensit
cardiac
troponin
increas
rapidli
day
diseas
onset
wherea
lactat
dehydrogenas
increas
survivor
nonsurvivor
earli
stage
ill
decreas
day
survivor
median
time
ill
onset
dyspnoea
similar
survivor
nonsurvivor
median
durat
dyspnoea
day
survivor
tabl
figur
survivor
median
durat
fever
day
cough
persist
day
iqr
figur
survivor
still
cough
discharg
nonsurvivor
still
cough
time
death
dynam
profil
fever
cough
dyspnoea
shown
appendix
p
sepsi
develop
median
day
ill
onset
among
patient
follow
ard
day
acut
cardiac
injuri
day
acut
kidney
injuri
day
secondari
infect
day
initi
time
durat
systemat
corticosteroid
use
also
similar
two
group
among
nonsurvivor
median
time
ill
onset
day
sepsi
day
ard
day
acut
cardiac
injuri
tabl
among
survivor
secondari
infect
acut
kidney
injuri
acut
cardiac
injuri
observ
one
patient
occur
day
acut
kidney
injuri
day
secondari
infect
day
acut
cardiac
injuri
ill
onset
median
time
dyspnoea
intub
day
iqr
patient
receiv
invas
mechan
ventil
time
invas
mechan
ventil
occurr
ventilatorassoci
pneumonia
day
figur
retrospect
cohort
studi
identifi
sever
risk
factor
death
adult
wuhan
hospitalis
particular
older
age
ddimer
level
greater
higher
sofa
score
admiss
associ
higher
odd
inhospit
death
addit
elev
level
blood
highsensit
cardiac
troponin
lactat
dehydrogenas
lymphopenia
commonli
seen
sever
ill
sustain
viral
detect
throat
sampl
observ
survivor
nonsurvivor
previous
older
age
report
import
independ
predictor
mortal
sar
mer
current
studi
confirm
increas
age
associ
death
patient
previou
studi
macaqu
inocul
sarscov
found
older
macaqu
stronger
host
innat
respons
viru
infect
younger
adult
increas
differenti
express
gene
associ
inflamm
wherea
express
type
interferon
beta
reduc
agedepend
defect
tcell
bcell
function
excess
product
type
cytokin
could
lead
defici
control
viral
replic
prolong
proinflammatori
respons
potenti
lead
poor
outcom
sofa
score
good
diagnost
marker
sepsi
septic
shock
reflect
state
degre
multiorgan
dysfunct
although
bacteri
infect
usual
regard
lead
caus
sepsi
viral
infect
also
caus
sepsi
syndrom
previous
determin
sepsi
occur
nearli
adult
communityacquir
pneumonia
due
viral
infect
current
studi
found
half
patient
develop
sepsi
addit
found
patient
white
blood
cell
count
per
l
procalcitonin
ngml
bacteri
pathogen
detect
patient
admiss
sepsi
common
complic
might
directli
caus
infect
research
need
investig
pathogenesi
sepsi
ill
cardiac
complic
includ
new
worsen
heart
failur
new
worsen
arrhythmia
myocardi
infarct
common
patient
pneumonia
cardiac
arrest
occur
inpati
pneumonia
risk
factor
cardiac
event
pneumonia
includ
older
age
preexist
cardiovascular
diseas
greater
sever
pneumonia
present
coronari
heart
diseas
also
found
associ
acut
cardiac
event
poor
outcom
influenza
respiratori
viral
infect
studi
increas
highsensit
cardiac
troponin
hospitalis
found
half
die
first
autopsi
woman
chronic
renal
failur
jinyintan
hospit
show
acut
myocardi
infarct
data
publish
person
commun
pathologist
chines
academi
scienc
inpati
pneumonia
increas
coagul
activ
mark
increas
ddimer
concentr
studi
found
ddimer
greater
associ
fatal
outcom
high
level
ddimer
report
asso
ciation
mortal
patient
infect
sepsi
identifi
emerg
depart
contri
butori
mechan
includ
system
proinflammatori
cytokin
respons
mediat
atherosclerosi
directli
contribut
plaqu
ruptur
local
inflamm
induct
procoagul
factor
haemodynam
chang
predispos
ischaemia
thrombosi
addit
angiotensin
convert
enzym
receptor
express
myocyt
vascular
endotheli
cell
least
theoret
potenti
possibl
direct
cardiac
involv
viru
note
interstiti
mononuclear
inflammatori
infiltr
heart
tissu
level
durat
infecti
viru
replic
import
factor
assess
risk
tran
mission
guid
decis
regard
isol
patient
coronaviru
rna
detect
sensit
viru
isol
studi
use
qualit
quantit
viral
rna
test
potenti
marker
infecti
coronaviru
sarscov
viral
rna
detect
respiratori
specimen
third
patient
long
week
diseas
onset
similarli
dura
tion
merscov
rna
detect
lower
respiratori
speciman
persist
least
week
wherea
durat
rna
detect
well
characteris
current
studi
found
detect
rna
persist
median
day
survivor
sustain
death
nonsurvivor
import
implic
patient
isol
decis
make
guidanc
around
length
antivir
treatment
sever
influenza
viru
infect
prolong
viral
shed
associ
fatal
outcom
delay
antivir
treatment
independ
risk
factor
prolong
viru
detect
similarli
effect
antivir
treatment
might
improv
outcom
although
observ
shorten
viral
shed
durat
lopinavirritonavir
treatment
cur
rent
studi
ran
domis
clinic
trial
lopinavirritonavir
intraven
remdesivir
treatment
current
progress
studi
limit
first
due
retrospect
studi
design
laboratori
test
done
patient
includ
lactat
dehydrogenas
serum
ferritin
therefor
role
might
underestim
predict
inhospit
death
second
patient
sometim
transfer
late
ill
two
includ
hospit
lack
effect
antivir
inadequ
adher
standard
support
therapi
highdos
corticosteroid
use
might
also
contribut
poor
clinic
outcom
patient
third
estim
durat
viral
shed
limit
frequenc
respiratori
specimen
collect
lack
quantit
viral
rna
detect
rel
low
posit
rate
rna
detect
throatswab
fourth
exclud
patient
still
hospit
jan
thu
rel
sever
diseas
earlier
stage
case
fatal
ratio
studi
reflect
true
mortal
last
least
interpret
find
might
limit
sampl
size
howev
includ
adult
patient
two
design
hospit
believ
studi
popul
repres
case
diagnos
treat
wuhan
best
knowledg
largest
retrospect
cohort
studi
among
patient
experienc
definit
outcom
found
older
age
higher
sofa
score
elev
ddimer
admiss
risk
factor
death
adult
patient
prolong
viral
shed
provid
rational
test
novel
coronaviru
antivir
intervent
effort
improv
outcom
bc
hc
idea
design
studi
full
access
data
studi
take
respons
integr
data
accuraci
data
analysi
bc
fz
gf
zl
jxi
yl
draft
paper
bc
fz
rd
gf
zl
xg
hl
ywa
analysi
author
critic
revis
manuscript
import
intellectu
content
gave
final
approv
version
publish
fz
rd
gf
zl
yl
bs
lg
ywe
xw
jxu
st
yz
collect
data
author
agre
account
aspect
work
ensur
question
relat
accuraci
integr
part
work
appropri
investig
resolv
declar
compet
interest
